Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

2,999 public trials 572 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 119 Denver, Colorado, United States
  • Local Institution - 104 Tampa, Florida, United States
  • Local Institution - 108 Atlanta, Georgia, United States
  • Local Institution - 112 Chicago, Illinois, United States
View all 49 locations
View Trial Details
Active, Not Recruiting

MInimal Residual Disease Adapted Strategy

NCT04934475

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Institut Jules Bordet Brussels, Belgium
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Grand Hôpital de Charleroi - Site de Notre-Dame Charleroi, Belgium
  • Hôpital Jolimont Haine-Saint-Paul, Belgium
View all 73 locations
View Trial Details
Active, Not Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

NCT04756401

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • State University of New York Upstate Medical University Syracuse, New York, United States
  • UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
  • Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina, United States
View Trial Details
Active, Not Recruiting

Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

NCT03225417

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • ICO- Hospital Germans Trias i Pujol Badalona, Spain
  • Hospital Clinic de Barcelona Barcelona, Spain
  • Hospital de la Santa Creu I Sant Pau Barcelona, Spain
  • Hospital Universitario Vall D´Hebrón Barcelona, Spain
View Trial Details
Active, Not Recruiting

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

NCT00048958

Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Blood Protein Disorders, +21 more
Locations
  • Rebecca and John Moores UCSD Cancer Center La Jolla, California, United States
  • Camino Medical Group - Treatment Center Mountain View, California, United States
  • Kaiser Permanente Medical Office -Vandever Medical Office San Diego, California, United States
  • Naval Medical Center - San Diego San Diego, California, United States
View all 137 locations
View Trial Details
Active, Not Recruiting

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

NCT04144387

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Institut Jules Bordet Brussels, Belgium
  • CHU UCL Namur ASBL Site Godinne Yvoir, Belgium
  • Centre Hospitalier Abbeville, France
View all 90 locations
View Trial Details
Active, Not Recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

NCT03915184

Conditions
Blood Protein Disorders, Carcinoma, Cardiovascular Diseases, +14 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UCSF San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

NCT03289299

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • University of Kansas Cancer Center Westwood, Kansas, United States
View Trial Details

Related conditions